You are here

Article Text

Article menu
Download PDFPDF
PostScript
Letter
Tocilizumab in COVID-19 management: addressing time of starting treatment
  1. Sajad Khiali,
  2. Taher Entezari-Maleki
  1. Tabriz University of Medical Sciences, Tabriz, Iran
  1. Correspondence to Dr Taher Entezari-Maleki, Tabriz University of Medical Sciences, Tabriz 5166614766, Iran; tentezari{at}gmail.com

https://doi.org/10.1136/ejhpharm-2021-003149

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Identifying effective and safe therapies for the management of patients with coronavirus disease 2019 (COVID-19) is crucial in the control of the pandemic. The critical role of immune system dysregulation in the pathophysiology of multisystem organ dysfunction following COVID-19 is well recognised. Several attempts have been made to investigate multiple anti-inflammatory drugs with beneficial effects in the management of COVID-19. Recently, the US Food and Drug Administration issued an emergency use authorisation (EUA) for the use of tocilizumab in combination with corticosteroids in hospitalised patients with COVID-19 aged ≥2 years who require non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation. However, there are uncertainties regarding the time, dose and duration of administration. Some efforts have been made to answer these questions.1 2 …

    View Full Text

    Footnotes

    • Contributors All authors have contributed equally to the development of the work.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; internally peer reviewed.